Verona Pharma, which is developing inhaled treatments for respiratory diseases, raised $78 million by offering 5.8 million shares at $13.50, in line with the expected price of $13.49. Verona Pharma plans to list on the Nasdaq under the symbol VRNA. Jefferies and Stifel acted as lead managers on the deal.
